In Coronavirus Assay Validation for Emergency Use, Labs Encounter Multiple Pain Points

Mar 11, 2020

|

This story has been updated to include additional manufacturing capabilities of authorized reagent suppliers.

NEW YORK – Labs developing their own assays for SARS-CoV-2 virus detection in patients are coming across unexpected bottlenecks and hurdles as they rush toward US Food and Drug Administration emergency use authorization.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

In Coronavirus Assay Validation for Emergency Use, Labs Encounter Multiple Pain Points

To read the full story....

Breaking News

Rhinostics Licenses Procter & Gamble Nasal Swab for COVID-19 Testing

FIND, Unitaid Ink First Agreement to Enable COVID-19 Antigen Tests at $2.50 Apiece

Oppenheimer Initiates Coverage of DermTech With Outperform Rating

Invitae Prices $400M Common Stock Offering

Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

In Brief This Week: Myriad Genetics, Precipio, LumiraDx, Guardant Health, and More

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

What's Popular?

CDC Study Finds Abbott BinaxNow SARS-CoV-2 Antigen Test Less Sensitive Than PCR, But Still Useful

Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

Lucira Health Files for $115M IPO

Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

Sponsorships